Read by QxMD icon Read


Hui-Juan Li, Wen-Xing Li, Shao-Xing Dai, Yi-Cheng Guo, Jun-Juan Zheng, Jia-Qian Liu, Qian Wang, Bi-Wen Chen, Gong-Hua Li, Jing-Fei Huang
The lack of early diagnostic markers and novel therapeutic targets for clear cell renal cell carcinoma (ccRCC) negatively affects patient prognosis. Cancer metabolism is an attractive area for the understanding of the molecular mechanism of carcinogenesis. The present study attempted to identify metabolic changes from the view of the expression of metabolism-associated genes between control samples and those of ccRCC at different disease stages. Data concerning ccRCC gene expression obtained by RNA-sequencing was obtained from The Cancer Genome Atlas and data on metabolism-associated genes were extracted using the Recon2 model...
February 2018: Oncology Letters
Hengchuan Su, Hongkai Wang, Guohai Shi, Hailiang Zhang, Fukang Sun, Dingwei Ye
OBJECTIVE: In order to identify potential novel biomarkers of advanced clear cell renal cell carcinoma (ccRCC), we re-evaluated published long non-coding RNA (lncRNA) expression profiling data. MATERIALS AND METHODS: The lncRNA expression profiles in ccRCC microarray dataset GSE47352 were analyzed and an independent cohort of 61 clinical samples including 21 advanced and 40 localized ccRCC patients was used to confirm the most statistically significant lncRNAs by real time PCR...
January 13, 2018: European Journal of Surgical Oncology
Walter Henriques da Costa, Isabela Werneck da Cunha, Aline Fusco Fares, Stephania M Bezerra, Luciana Shultz, Diego Abreu Clavijo, Deusdedit Vieira da Silva, George Jabboure Netto, Gustavo Cardoso Guimaraes, Stenio de Cassio Zequi
PURPOSE: To evaluate the prognostic impact of immunohistochemical expression of BAP1 and PBRM1 in patients with early stage (pT1-pT2N0M0) clear cell renal cell carcinoma (ccRCC). PATIENTS AND METHODS: A total of 441 consecutive patients treated surgically for stages I and II (TNM-AJCC 2010) ccRCC between 1990 and 2016 were selected. All cases were reviewed for uniform reclassification and the most representative tumor areas were selected for the construction of a tissue microarray...
February 6, 2018: Urologic Oncology
Qi Bai, Li Liu, Wei Xi, Jiajun Wang, Yu Xia, Yang Qu, Ying Xiong, Qilai Long, Jiejie Xu, Jianming Guo
Background: Sialyltransferase ST6GalNAc-1 is highly expressed in tumor cells and associated with tumor aggressiveness and poor prognosis. In the present study, we aimed to investigate the clinical and prognostic significance of sialyltransferase ST6GalNAc-1 in patients with non-metastatic ccRCC. Results: High expression of ST6GalNAc-1 in tumor tissue was an independent prognostic factor for overall survival (p<0.001) and recurrence free survival (p<0.001) in multivariate analysis...
January 9, 2018: Oncotarget
Jiantao Xiao, Qing Shi, Weiguo Li, Xingyu Mu, Jintao Peng, Mingzi Li, Mulin Chen, Huabing Huang, Chenji Wang, Kun Gao, Jie Fan
The α-arrestins domain-containing 1 and 3 (ARRDC1 and ARRDC3) are two members of the α-arrestins family. Yes-associated protein 1 (YAP1) is a key downstream transcription co-activator of the Hippo pathway essential for cancer initiation, progression, or metastasis in clear cell renal cell carcinoma (ccRCC). The aim of this work was to elucidate the role of the α-arrestins in ccRCC tumorigenesis by identifying molecular interacting factors and exploring potential mechanisms. In this study, we identified YAP1 as a novel ARRDC3 interacting protein in RCC cells through tandem affinity purification and mass spectrometry...
2018: American Journal of Cancer Research
Jeong Hwan Park, Minsun Jung, Kyung Chul Moon
Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma (RCC), and it has an unfavourable prognosis compared to other RCCs. Plant homeodomain finger 2 (PHF2) and CCATT/enhancer binding protein α (C/EBPα) play a role in the epigenetic regulation of adipogenesis, and their tumour suppressive functions have been elucidated. This study aimed to assess the nuclear expression of PHF2 and C/EBPα in ccRCC and to evaluate their role in pathogenesis and prognosis. The nuclear expression of PHF2 and C/EBPα was evaluated in 344 cases of ccRCC by immunohistochemistry, and adipogenesis was assessed based on cytoplasmic features...
January 2, 2018: Oncotarget
Frauke G Heinemann, Yuri Tolkach, Mario Deng, Doris Schmidt, Sven Perner, Glen Kristiansen, Stefan C Müller, Jörg Ellinger
Background: MicroRNAs (miRNA) play a relevant role in carcinogenesis, cancer progression, invasion, and metastasis. Thus, they can serve as diagnostic/prognostic biomarkers. The knowledge on circulating miRNAs for clear cell renal cell carcinomas (ccRCC) is limited. Our study was designed to identify novel biomarkers for ccRCC patients. Results: The serum small RNA expression profile was determined in 18 ccRCC and 8 patients with benign renal tumors (BRT) using small RNA sequencing...
2018: Clinical Epigenetics
Bradley C Leibovich, Christine M Lohse, John C Cheville, Harras B Zaid, Stephen A Boorjian, Igor Frank, R Houston Thompson, William P Parker
BACKGROUND: Predicting oncologic outcomes is important for patient counseling, clinical trial design, and biomarker study testing. OBJECTIVE: To develop prognostic models for progression-free (PFS) and cancer-specific survival (CSS) in patients with clear cell renal cell carcinoma (ccRCC), papillary RCC (papRCC), and chromophobe RCC (chrRCC). DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort review of the Mayo Clinic Nephrectomy registry from 1980 to 2010, for patients with nonmetastatic ccRCC, papRCC, and chrRCC...
February 2, 2018: European Urology
Mingchao Wang, Yin Sun, Junjie Xu, Jieyang Lu, Kefeng Wang, Dong-Rong Yang, Guosheng Yang, Gonghui Li, Chawnshang Chang
While testicular nuclear receptor 4 (TR4) may promote prostate cancer (PCa) metastasis, its roles in the clear cell renal cell carcinoma (ccRCC) remains unclear. Here we found a higher expression of TR4 in ccRCC tumors from patients with distant metastases than those from metastasis-free patients, suggesting TR4 may play positive roles in the ccRCC metastasis. Results from in vitro multiple ccRCC cell lines also confirmed TR4's positive roles in promoting ccRCC cell invasion/migration via altering the microRNA (miR-32-5p)/TR4/HGF/Met/MMP2-MMP9 signaling...
February 2, 2018: International Journal of Cancer. Journal International du Cancer
Naibijiang Maolakuerban, Baihetiya Azhati, Hamulati Tusong, Asimujiang Abula, Anniwaer Yasheng, Ayiding Xireyazidan
In this study, we investigated the mechanism of miR-200c-3p and SLC6A1 in regulating cell activity of clear cell renal cell carcinoma (CCRCC). The mRNA and miRNA expressions of tissue specimens were analyzed by CapitalBio Corporation (Beijing, China). The expression of SLC6A1 in CCRCC cells was examined through qRT-PCR and western blot. The migration and invasion ability of 786-O cells was testified by transwell assay after transfected. 786-O cell proliferation ability was detected by MTT assay. Dual luciferase reporter assay verified the association between SLC6A1 and miR-200c-3p...
February 2, 2018: Cancer Biology & Therapy
Xiaohui Gong, Xianjin Du, Yong Xu, Wenze Zheng
BACKGROUND/AIMS: LINC00037 has previously been reported to be up-regulated in clear cell renal cell carcinoma (ccRCC), however, the underlying mechanism remained unknown. In this study, we designed to investigate the functional role of LINC00037 in ccRCC Methods: LINC00037 knockdown and re-expressing 786-O and A498 cells were established. CCK8 assay and EdU assay were performed to evaluate the proliferation rates of ccRCC cells. Flow cytometry assay was performed to detect the cell apoptosis and cell cycle...
January 30, 2018: Cellular Physiology and Biochemistry
Jun Nishida, Kohei Miyazono, Shogo Ehata
TGF-β regulates both the tumor-forming and migratory abilities of various types of cancer cells. However, it is unclear how the loss of TGF-β signaling components affects these abilities in clear-cell renal cell carcinoma (ccRCC). In this study, we investigated the role of TGFBR3 (TGF-β type III receptor, also known as betaglycan) in ccRCC. Database analysis revealed decreased expression of TGFBR3 in ccRCC tissues, which correlated with poor prognosis in patients. Orthotopic inoculation experiments using immunocompromised mice indicated that low TGFBR3 expression in ccRCC cells enhanced primary tumor formation and lung metastasis...
February 2, 2018: Oncogene
Jeffrey G Himmelman, Jennifer Merrimen, Kara Matheson, Chris Theriault, Lori A Wood
INTRODUCTION: Provincial/territorial cancer registries (PTCRs) are the mainstay for Canadian population-based cancer statistics. Each jurisdiction captures this data in a population-based registry, including the Nova Scotia Cancer Registry (NSCR). The goal of this study was to describe data from the NSCR regarding renal cell carcinoma (RCC) pathology subtype and method of diagnosis and compare it to the actual pathology reports to determine the accuracy of diagnosis and histological subtype assignment...
September 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
Lin Zhou, Daming Cui, Lijin Feng, Liang Gao
Chordomas are uncommon, locally invasive chordate tumors, which are mostly observed in the axial skeleton. Numerous papers have described similar patients around different anatomic locations; however, rare document previously reported that intracranial chordoma was associated with clear cell renal cell carcinoma (ccRCC). The authors report a 51-year-old male patient with a history of right radical nephrectomy for ccRCC presented to us with progressive blurred vision. Ophthalmic examination showed vision loss and visual field defects...
January 19, 2018: Journal of Craniofacial Surgery
Agnieszka Sliwinska-Jewsiewicka, Anna E Kowalczyk, Bartlomiej E Krazinski, Janusz Godlewski, Przemyslaw Kwiatkowski, Jolanta Kiewisz, Jedrzej Grzegrzolka, Piotr Dziegiel, Zbigniew Kmiec
BACKGROUND/AIM: SATB2 (special AT-rich sequence-binding protein 2) is a DNA-binding protein that is involved in transcriptional regulation and chromatin remodeling. SATB2 protein has been described as a promising novel marker in several human cancers. PATIENTS AND METHODS: This study compared SATB2 expression in tumor and matched unchanged renal tissues collected from 57 patients with clear cell renal cell carcinoma (ccRCC). SATB2 mRNA levels were determined by quantitative polymerase chain reaction, while SATB2 protein expression was estimated by immunohistochemistry...
February 2018: Anticancer Research
M Sadat-Khonsari, M Papayannis, P Schriefer, L Kluth, C Meyer, V Schüttfort, M Regier, M Rink, F Chun, M Fisch, A Becker
INTRODUCTION AND OBJECTIVE: Renal tumor biopsy is recommended for histological diagnosis of radiologically indeterminate renal masses, to select patients with small-renal masses for surveillance approaches, before ablative treatments and to confirm metastatic spread of renal cell cancer (RCC), according to the EAU guidelines. We aimed to determine outcomes of patients with suspicious renal masses with initial finding of regular renal tissue in renal tumor biopsies. METHODS: Retrospective database analysis of 101 patients undergoing CT-guided-, percutaneous renal tumor biopsies in local anesthesia...
January 25, 2018: World Journal of Urology
Haibing Xiao, Lin Bao, Wen Xiao, Hailong Ruan, Zhengshuai Song, Yan Qu, Ke Chen, Xiaoping Zhang, Hongmei Yang
Background: Many long intergenic noncoding RNAs (lincRNAs) are encoded in the human genome. However, their biological functions, molecular mechanisms and prognostic values associated with clear cell renal cell carcinoma (ccRCC) have yet to be elucidated. Methods: We screened the lncRNAs' profile in ccRCC from The Cancer Genome Atlas (TCGA) database, and selected Lucat1 for further study. MTS, colony formation assay and transwell assay were performed to examine the effect of Lucat1 on proliferation and metastasis of ccRCC...
December 26, 2017: Oncotarget
Cristina Bianchi, Chiara Meregalli, Silvia Bombelli, Vitalba Di Stefano, Francesco Salerno, Barbara Torsello, Sofia De Marco, Giorgio Bovo, Ingrid Cifola, Eleonora Mangano, Cristina Battaglia, Guido Strada, Giuseppe Lucarelli, Robert H Weiss, Roberto A Perego
Clear cell renal cell carcinoma (ccRCC) has a poor prognosis despite novel biological targeted therapies. Tumor aggressiveness and poor survival may correlate with tumor grade at diagnosis and with complex metabolic alterations, also involving glucose and lipid metabolism. However, currently no grade-specific metabolic therapy addresses these alterations. Here we used primary cell cultures from ccRCC of low- and high-grade to investigate the effect on energy state and reduced pyridine nucleotide level, and on viability and proliferation, of specific inhibition of glycolysis with 2-deoxy-D-glucose (2DG), or fatty acid oxidation with Etomoxir...
December 26, 2017: Oncotarget
Fan Zhang, Xin Ma, Hongzhao Li, Yu Zhang, Xintao Li, Luyao Chen, Gang Guo, Yu Gao, Liangyou Gu, Yongpeng Xie, Junyao Duan, Xu Zhang
Forkhead box K2 (FOXK2) belongs to the forkhead box transcription factor family. Recent studies have revealed that FOXK2 plays essential roles in cancer cell proliferation and survival. However, the biological function of FOXK2 in renal cell carcinoma remains unexplored. In this study, we demonstrated that FOXK2 mRNA and protein levels were decreased in clear-cell renal cell carcinoma (ccRCC) tissues compared with that in corresponding non-tumor renal tissues, and decreased FOXK2 levels were associated with poor prognosis in ccRCC patients after nephrectomy...
January 25, 2018: International Journal of Cancer. Journal International du Cancer
Ulka Vaishampayan
With no therapy specifically approved for non-clear cell cancers of the kidney, this disease remains an orphan site. Clear cell renal cancers (ccRCC) have seen a flurry of activity with multiple agents gaining Food and Drug Administration (FDA) approval in recent years. Simultaneously, non-clear cell RCC (ncRCC) have also seen a fair share of activity and exploration of new agents in development but no specific FDA approvals. Non-clear cell RCC is a mixed bag of multiple types of tumors originating in the kidney with distinct clinical molecular and genetic characteristics that vary significantly from clear cell carcinoma of the kidney...
January 24, 2018: Current Treatment Options in Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"